新冠疫情期间美国一家全国性零售药房接种mRNA-1273疫苗的相关因素
研究分析Walgreens药房2020年12月18日至2022年2月28日接种mRNA-1273疫苗的4,870,915名患者数据,约85%接种第二剂,仅51.0%免疫功能低下者接种第三剂,年龄、种族/民族、社区特征与接种完成相关。
要点
- 研究期间约85%患者接种第二剂mRNA-1273疫苗。
- 仅51.0%免疫功能低下患者按建议接种第三剂。
- 年龄较大、种族/民族、社区保险水平高及低社会脆弱性地区与按时接种第二剂相关。
核心结论
- 超过80%患者按CDC建议按时接种第二剂mRNA-1273疫苗。
- 患者人口学特征和社区特征与疫苗接种及系列完成相关。
- 作者认为应进一步研究促进大流行期间疫苗系列完成的新方法。
研究设计与样本
- 研究将Walgreens药房数据与公开数据集关联,分析mRNA-1273疫苗第一剂系列及多剂完成趋势。
- 纳入2020年12月18日至2022年2月28日在Walgreens接种第一剂mRNA-1273疫苗的合格患者。
- 样本量N=4,870,915名接种至少1剂mRNA-1273疫苗的患者。
主要发现
- 患者中57.0%为白人,52.6%为女性,平均年龄49.4岁。
- 研究期间约85%患者接种第二剂。
- 仅51.0%免疫功能低下患者按建议接种第三剂。
- 早期接种者占60.6%。
- 与按时接种第二剂相关的因素包括年龄较大、种族/民族、为第一剂旅行≤10英里、社区健康保险水平较高、居住在社会脆弱性较低地区。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prompted accelerated vaccine development of novel messenger RNA (mRNA)-based vaccines by Moderna and Pfizer, which received FDA Emergency Use Authorization in December 2020. The purpose of this study was to examine trends in primary series administration and multi-dose completion rates with Moderna's mRNA-1273 vaccine administered at a United States retail pharmacy. METHODS: Walgreens pharmacy data were joined to publicly available data sets to examine trends in mRNA-1273 primary series and multi-dose completion across patient race/ethnicity, age, gender, distance to first vaccination, and community characteristics. Eligible patients received their first dose of mRNA-1273 administered by Walgreens between December 18, 2020 and February 28, 2022. Variables significantly associated with on-time second dose (all patients) and third dose (immunocompromised patients) in univariate analyses were included in linear regression models. A subset of patients in selected states were studied to identify differences in early and late vaccine adoption. RESULTS: Patients (N = 4,870,915) who received ≥ 1 dose of mRNA-1273 were 57.0% White, 52.6% female, and averaged 49.4 years old. Approximately 85% of patients received a second dose during the study period. Factors associated with on-time second dose administration included older age, race/ethnicity, traveling ≤ 10 miles for the first dose, higher community-level health insurance, and residing in areas with low social vulnerability. Only 51.0% of immunocompromised patients received the third dose as recommended. Factors associated with third dose administration included older age, race/ethnicity, and small-town residence. Early adopters accounted for 60.6% of patients. Factors associated with early adoption included older age, race/ethnicity, and metropolitan residence. CONCLUSION: Over 80% of patients received their on-time second dose of mRNA-1273 vaccine per CDC recommendations. Patient demographics and community characteristics were associated with vaccine receipt and series completion. Novel approaches to facilitate series completion during a pandemic should be further studied.
引用
- Roberts-McCarthy E, Buck PO, Smith-Ray RL, et al. Factors associated with receipt of mRNA-1273 vaccine at a United States national retail pharmacy during the COVID-19 pandemic. Vaccine. 2023. PMID: 37296016. doi:10.1016/j.vaccine.2023.03.076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。